New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
05:22 EDTTROVTrovagene to study transrenal BRAF mutations in primary and metastatic cancers
Trovagene announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. Researchers will use Trovagene's proprietary transrenal DNA, or TrDNA, detection technology to evaluate BRAF mutation status in urine as compared to tissue biopsy. The study also calls for monitoring of mutation levels in the urine at planned intervals during and after treatment to assess outcomes including: response rate; stable disease; progression-free survival; and overall survival. Results from patients who receive therapy that reflects their BRAF mutation status will be compared to outcomes for patients who receive standard-of-care therapy regardless of mutation status.
News For TROV From The Last 14 Days
Check below for free stories on TROV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
11:13 EDTTROVTrovagene data increases IP monetization potential, says Maxim
Subscribe for More Information
08:10 EDTTROVTrovagene presents urine-based HPV assay clinical results
Trovagene announced that results from two independent clinical studies were presented at the 29th International Papillomavirus Conference. Results from both pilot studies consistently demonstrated that the company's urine-based assay for the detection of high-risk HPV had high sensitivity for identifying women with high grade cervical intraepithelial neoplasia. Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing. In an oral presentation entitled "Evaluation of Two Urine-Based HPV Assays In Comparison to Cervical HPV Detection and High-Grade CIN Among Women Attending a Colposcopy Clinic," results from a population-based National Cancer Institute study, conducted at the University of Oklahoma Health Sciences Center, were released. A second presentation entitled "A Comparison of Urine Collection Times for the Detection of High-Risk HPV Infection in Women" included results from a study conducted at University of North Carolina, Chapel Hill. The company said, "The positive study results presented at the IPV Conference are very encouraging as we continue to conduct clinical studies to evaluate the performance of our urine-based high-risk HPV assay as a viable alternative to conventional HPV testing from a cervical specimen. A significantly larger, blinded study which compares sensitivity of detecting high-risk HPV in patients with CIN2/3 in urine versus cervical samples is ongoing and results will be reported by 1Q15."
August 18, 2014
07:59 EDTTROVTrovagene current levels offer buying opportunity, says Maxim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use